High dose therapy followed by infusion of autologous bone narrow has become a major treatment option for an increasing number of poor prognosis non-Hodgkin's lymphoma (NHL) patients. In our study we analyzed the outcome of autologous bone marrow transplantation (ABMT) in 44 high grade NHL patients transplanted at our institution between 1985 and 1992. Median age was 31 years (range 12-61); nineteen were in partial remission (PR) after first line chemotherapy and 25 in sensitive relapse (SR). Of the 25 patients transplanted in SR, 14 relapsed after a median time of 5.5 months (range 1-26), 8 are in complete remission after a median follow up of 41.5 months and three died from toxicity. Of the 19 patients grafted in PR, 11 are alive and progression free after a median follow up of 52 months, while 8 relapsed at a median time of 5 months. The overall progression free survival (PFS) projected at 6 years is 35% with a 47% PFS for patients transplanted in PR and 28% for patients in SR. In conclusion, high dose therapy and ABMT has achieved widespread use as salvage therapy for patients with relapsed/refractory high grade NHL. In particular, our experience confirms that myeloablative treatment is a safe and well tolerated procedure for patients in PR, that may be easily applied as early salvage therapy without major toxicities.

Autologous bone marrow transplantation in 44 patients with aggressive non-Hodgkin's lymphoma at University ''La Sapienza'' of Rome / Saveria, Capria; Vignetti, Marco; Anna, Proia; Roberta, Caruso; Lorenzo, Coppola; Enrica, Orsini; Meloni, Giovanna. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 23:1-2(1996), pp. 147-151. [10.3109/10428199609054814]

Autologous bone marrow transplantation in 44 patients with aggressive non-Hodgkin's lymphoma at University ''La Sapienza'' of Rome

VIGNETTI, Marco;MELONI, Giovanna
1996

Abstract

High dose therapy followed by infusion of autologous bone narrow has become a major treatment option for an increasing number of poor prognosis non-Hodgkin's lymphoma (NHL) patients. In our study we analyzed the outcome of autologous bone marrow transplantation (ABMT) in 44 high grade NHL patients transplanted at our institution between 1985 and 1992. Median age was 31 years (range 12-61); nineteen were in partial remission (PR) after first line chemotherapy and 25 in sensitive relapse (SR). Of the 25 patients transplanted in SR, 14 relapsed after a median time of 5.5 months (range 1-26), 8 are in complete remission after a median follow up of 41.5 months and three died from toxicity. Of the 19 patients grafted in PR, 11 are alive and progression free after a median follow up of 52 months, while 8 relapsed at a median time of 5 months. The overall progression free survival (PFS) projected at 6 years is 35% with a 47% PFS for patients transplanted in PR and 28% for patients in SR. In conclusion, high dose therapy and ABMT has achieved widespread use as salvage therapy for patients with relapsed/refractory high grade NHL. In particular, our experience confirms that myeloablative treatment is a safe and well tolerated procedure for patients in PR, that may be easily applied as early salvage therapy without major toxicities.
1996
high-dose chemotherapy; nhl; partial remission; sensitive relapse
01 Pubblicazione su rivista::01a Articolo in rivista
Autologous bone marrow transplantation in 44 patients with aggressive non-Hodgkin's lymphoma at University ''La Sapienza'' of Rome / Saveria, Capria; Vignetti, Marco; Anna, Proia; Roberta, Caruso; Lorenzo, Coppola; Enrica, Orsini; Meloni, Giovanna. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 23:1-2(1996), pp. 147-151. [10.3109/10428199609054814]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/422393
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact